A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution.

Author(s): Gold MH, Rao J, Goldman MP, Bridges TM, Bradshaw VL, Boring MM, Guider AN

Affiliation(s): Gold Skin Care Center, Tennessee Clinical Research Center Nashville, TN 37215, USA. drgold@goldskincare.com

Publication date & source: 2005-01, J Drugs Dermatol., 4(1):64-70.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

BACKGROUND: Blue light sources have been shown to be effective in the treatment of mild to moderate inflammatory acne vulgaris lesions. OBJECTIVE: We evaluated the safety and efficacy of a new blue light source in the treatment of mild to moderate inflammatory acne vulgaris in comparison to topical 1% clindamycin solution. RESULTS: Blue light therapy reduced inflammatory acne vulgaris lesions by an average of 34%, as compared to 14% for topical 1% clindamycin solution. CONCLUSIONS: The blue light source presented in this report is a safe and effective treatment option available to our patients with mild to moderate inflammatory acne lesions.